Regenicin, Inc. (RGIN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Little Falls, NJ, アメリカ. 現CEOは Randall E. McCoy.
RGIN を有する IPO日 2009-11-16, 3 名の正社員, に上場 Other OTC, 時価総額 $15.35K.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
